Paying for care
The temporary Medicare weight-care route
The Medicare GLP-1 Bridge has its own rules. GLP-1 is a body chemical that helps control appetite and blood sugar. Some weight medicines copy what it does.
A dated programme, with a set copay
As of September 26, 2026, CMS describes a temporary Bridge that starts on July 1, 2026 and ends on December 31, 2027.
The federal agency running Medicare and Medicaid is called CMS.
The copay, meaning the patient’s share, is $50 for a monthly supply of covered products for eligible patients.
It runs separately from Part D, Medicare’s usual way of paying for prescriptions. This is not a general change to weight-loss coverage law.
Who can use the Bridge?
The Bridge requires a prescription and prior authorisation, meaning approval before payment.
Patients must be at least 18 years old; weight and certain other health conditions affect eligibility.
Type 2 diabetes makes a person ineligible for this route because that condition goes through ordinary Part D.
If Part D covered the cost of a person’s GLP-1 medicine earlier in 2026, that person cannot use the Bridge that year.
You need either a separate prescription plan under Part D or Medicare Advantage with prescription benefits and care arrangements. For some other types of plan, qualifying also requires separate Part D coverage.
If ‘private fee-for-service’, ‘cost-contract’ or ‘PACE’ appears on your plan papers, ask whether you also have the separate Part D plan needed for the Bridge.
The prescription must be part of ongoing care that includes a planned approach to food and physical activity.
The weight and health checks
The health rules are judged as of when treatment began. They use BMI, a number comparing weight with height.
One route is a BMI of 35 or more. At a BMI of 30 or more, an added condition is needed. The added condition must be heart failure or high blood pressure as described below, or kidney disease that has reached at least stage 3a.
For that heart-failure route, the share of blood pumped out by the heart must remain normal. For the blood-pressure route, even with the two medicines, the top reading must exceed 140 or the bottom reading must exceed 90 mm Hg.
At a BMI of 27 or more, the added condition must be pre-diabetes, a previous heart attack or stroke, or reduced blood flow to the limbs with symptoms. Pre-diabetes is blood sugar above normal but below the diabetes range.
The Bridge also excludes people whose obstructive sleep apnea is moderate or severe. This means repeated breathing blockage during sleep. That condition uses ordinary Part D instead.
MASH also excludes a person when this fatty liver disease has moderate or advanced liver scarring without cirrhosis. Cirrhosis means severe, lasting liver scarring. This diagnosis uses Part D instead; not every fatty liver diagnosis rules someone out.
A prescription meant to lower the risk of major heart or stroke events also goes through Part D instead.
Ask the person prescribing and your plan to check your diagnosis and plan type against the full CMS rules. Ask them to explain any rule that keeps you out.
What the payment does not do
Your own spending on prescriptions covered by Part D has an annual cap. The $50 paid through the Bridge does not count toward that cap.
The Bridge has no extra payment help based on low income. Coupons cannot reduce the Bridge payment.
The included products are orforglipron (Foundayo), injectable and tablet forms of semaglutide (Wegovy), and tirzepatide (Zepbound) supplied in the KwikPen device.
Zepbound single-dose pens and vials, the small medicine bottles, are excluded. Ask the pharmacist to match the exact product and device to the Bridge list.